GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Savient Pharmaceuticals (FRA:BY7) » Definitions » Cyclically Adjusted Book per Share

Savient Pharmaceuticals (FRA:BY7) Cyclically Adjusted Book per Share : €0.00 (As of Sep. 2013)


View and export this data going back to . Start your Free Trial

What is Savient Pharmaceuticals Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Savient Pharmaceuticals's adjusted book value per share for the three months ended in Sep. 2013 was €-2.139. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €0.00 for the trailing ten years ended in Sep. 2013.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2024-05-15), Savient Pharmaceuticals's current stock price is €0.03. Savient Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2013 was €0.00. Savient Pharmaceuticals's Cyclically Adjusted PB Ratio of today is .


Savient Pharmaceuticals Cyclically Adjusted Book per Share Historical Data

The historical data trend for Savient Pharmaceuticals's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Savient Pharmaceuticals Cyclically Adjusted Book per Share Chart

Savient Pharmaceuticals Annual Data
Trend Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Savient Pharmaceuticals Quarterly Data
Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Mar14
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Savient Pharmaceuticals's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Savient Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Savient Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Savient Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Savient Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



Savient Pharmaceuticals Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Savient Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Sep. 2013 was:

Adj_Book= Book Value per Share /CPI of Sep. 2013 (Change)*Current CPI (Sep. 2013)
=-2.139/98.7900*98.7900
=-2.139

Current CPI (Sep. 2013) = 98.7900.

Savient Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
200312 2.518 77.758 3.199
200403 2.564 79.066 3.204
200406 2.164 80.037 2.671
200409 2.085 80.121 2.571
200412 1.911 80.290 2.351
200503 1.889 81.555 2.288
200506 2.356 82.062 2.836
200509 2.302 83.876 2.711
200512 2.419 83.032 2.878
200603 2.491 84.298 2.919
200606 2.412 85.606 2.783
200609 2.349 85.606 2.711
200612 2.630 85.142 3.052
200703 2.453 86.640 2.797
200706 2.323 87.906 2.611
200709 2.059 87.964 2.312
200712 1.809 88.616 2.017
200803 1.504 90.090 1.649
200806 1.238 92.320 1.325
200809 1.136 92.307 1.216
200812 0.874 88.697 0.973
200903 0.626 89.744 0.689
200906 0.131 91.003 0.142
200909 0.009 91.120 0.010
200912 0.673 91.111 0.730
201003 0.650 91.821 0.699
201006 0.745 91.962 0.800
201009 0.075 92.162 0.080
201012 0.537 92.474 0.574
201103 0.739 94.283 0.774
201106 0.435 95.235 0.451
201109 0.195 95.727 0.201
201112 -0.091 95.213 -0.094
201203 -0.443 96.783 -0.452
201206 -0.825 96.819 -0.842
201209 -1.224 97.633 -1.239
201212 -1.482 96.871 -1.511
201303 -1.745 98.209 -1.755
201306 -1.961 98.518 -1.966
201309 -2.139 98.790 -2.139

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Savient Pharmaceuticals  (FRA:BY7) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Savient Pharmaceuticals Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Savient Pharmaceuticals's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Savient Pharmaceuticals (FRA:BY7) Business Description

Industry
Traded in Other Exchanges
N/A
Address
Savient Pharmaceuticals, Inc., was founded in 1980. It develops, manufactures and markets products through the application of genetic engineering and related biotechnologies. The Company, and its wholly-owned Subsidiaries, is a specialty biopharmaceutical company focused on commercializing KRYSTEXXA (pegloticase) in the United States and completing the development and seeking regulatory approval outside of the United States for KRYSTEXXA, particularly in the European Union. It completed a promotional launch of KRYSTEXXA in the United States during the first quarter of 2011 with its sales force commencing field promotion to health care providers on February 28, 2011. The Company also sells and distributes branded and generic versions of oxandrolone, a drug used to promote weight gain following involuntary weight loss. The Company launched its authorized generic version of oxandrolone in December 2006 in response to the approval and launch of generic competition to Oxandrin. On January 1, 2012, KRYSTEXXA received a permanent J Code, which facilitates reimbursement to providers who treat patients suffering with RCG and who rely on Medicare and Medicaid. The manufacturing process for pegloticase, which is the drug substance of KRYSTEXXA, consists of the production through a recombinant process in which a genetically-engineered bacteria produces uricase, followed by its purification, PEGylation, further purification and formulation to produce the bulk pegloticase, which the company refers it as pegloticase drug substance. Pegloticase is aseptically filtered and filled into sterile, single dose vials to produce the KRYSTEXXA drug product. Its sales force targets rheumatologists and nephrologists with access to infusion centers and healthcare institutions, each of which treat adult patients suffering from RCG, as well as podiatrists who also treat patients with RCG. In March 2012, KRYSTEXXA was made available in the EU to healthcare professionals through a Named Patient Program. The Company sells its products to three drug wholesaler customers and various specialty distributors. Its research and development includes costs associated with the research and development of its KRYSTEXXA product prior to FDA approval and FDA-related post-marketing commitments for approved products (KRYSTEXXA post-approval). These costs mainly include pre-clinical and clinical studies and trials, personnel costs including compensation, consultants and contract research organizations, or CROs, quality control and assurance costs, regulatory costs and costs related to the development of commercial scale manufacturing capabilities for KRYSTEXXA, which also includes the costs of preparing Fujifilm to serve as its secondary source supplier of pegloticase drug substance for KRYSTEXXA in the United States. As of March 7, 2013, the company owned 14 issued U.S. patents and 154 issued foreign patents. It currently owns U.S. and several foreign registrations or applicat

Savient Pharmaceuticals (FRA:BY7) Headlines

No Headlines